Practical guideline for major hereditary thrombophilia

Thrombophilia encompasses a spectrum of disorders characterized by a predisposition to a hypercoagulable state, frequently culminating in thromboembolism.1 Among these, hereditary thrombophilia is defined as conditions arising from genetic mutations that disrupt hemostatic equilibrium. The clinical manifestations of thrombophilia primarily involve venous thromboembolism (VTE). Certain genetic variants may also predispose individuals to arterial thrombotic events.

While previous articles have provided guidance on indications for thrombophilia screening, discussions are largely confined to whether such screening informs the “duration of anticoagulation therapy.”1 This guideline, focusing specifically on hereditary thrombophilia, seeks to delineate the impact of diverse genetic factors on the selection of anticoagulant drug types and their duration. This work primarily addresses major hereditary thrombophilias. Gene polymorphisms with minimal contributions to disease, such as those associated with the ABO blood group, as well as exceedingly rare genetic mutations like F9 Padua, are not discussed here due to their limited clinical relevance or scant supporting evidence. The panel adopts the 2011 Oxford Center for Evidence-Based Medicine framework to assess the level of evidence (LoE) and make recommendations.

Indications for suspected thrombophilia

Recommendation: screening for thrombophilia is suggested under the following circumstances (LoE 4): (1) VTE at a young age, usually considered to be less than 50 years, particularly in the absence of strong provoking factors such as active malignancy, major surgery, or systemic vasculitis; (2) ischemic stroke or myocardial infarction at a young age, usually considered to be less than 40 years, especially in the absence of atherosclerotic risk factors; (3) neonatal purpura fulminans; (4) VTE at atypical sites, including cerebral, portal, mesenteric, or splenic veins; (5) multisite VTE during a single thrombotic event; (6) recurrent VTE without regional anatomic abnormalities; (7) poor response or progression of thrombosis during standard antithrombotic therapy; (8) warfarin-induced skin necrosis; and (9) VTE with a family history of thrombosis or diagnosed thrombophilia.